Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Dopamine D2 receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | g protein coupled receptor | Dopamine D2 receptor | 444 aa | 465 aa | 21.5 % |
Onchocerca volvulus | Dopamine D2 receptor | 444 aa | 418 aa | 23.0 % | |
Schistosoma mansoni | amine GPCR | Dopamine D2 receptor | 444 aa | 424 aa | 32.1 % |
Schistosoma mansoni | biogenic amine (dopamine) receptor | Dopamine D2 receptor | 444 aa | 494 aa | 26.3 % |
Schistosoma japonicum | ko:K04136 adrenergic receptor, alpha 1b, putative | Dopamine D2 receptor | 444 aa | 440 aa | 30.0 % |
Onchocerca volvulus | RB1-inducible coiled-coil protein 1 homolog | Dopamine D2 receptor | 444 aa | 474 aa | 23.4 % |
Schistosoma japonicum | Octopamine receptor, putative | Dopamine D2 receptor | 444 aa | 456 aa | 29.4 % |
Echinococcus granulosus | biogenic amine 5HT receptor | Dopamine D2 receptor | 444 aa | 429 aa | 31.7 % |
Echinococcus granulosus | g protein coupled receptor | Dopamine D2 receptor | 444 aa | 457 aa | 21.0 % |
Schistosoma mansoni | biogenic amine receptor | Dopamine D2 receptor | 444 aa | 452 aa | 30.1 % |
Schistosoma japonicum | ko:K04207 neuropeptide Y receptor Y5, putative | Dopamine D2 receptor | 444 aa | 386 aa | 19.7 % |
Schistosoma japonicum | ko:K04145 dopamine receptor D2, putative | Dopamine D2 receptor | 444 aa | 432 aa | 30.8 % |
Echinococcus multilocularis | serotonin receptor | Dopamine D2 receptor | 444 aa | 428 aa | 31.3 % |
Onchocerca volvulus | Glycoprotein hormone beta 5 homolog | Dopamine D2 receptor | 444 aa | 476 aa | 24.2 % |
Schistosoma mansoni | muscarinic acetylcholine (GAR) receptor | Dopamine D2 receptor | 444 aa | 487 aa | 23.8 % |
Loa Loa (eye worm) | hypothetical protein | Dopamine D2 receptor | 444 aa | 433 aa | 21.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium leprae | PROBABLE 1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE DXR (DXP REDUCTOISOMERASE) (1-DEOXYXYLULOSE-5-PHOSPHATE REDUCTOISOMERAS | 0.1738 | 1 | 0.5 |
Plasmodium vivax | 1-deoxy-D-xylulose 5-phosphate reductoisomerase, putative | 0.1738 | 1 | 0.5 |
Toxoplasma gondii | 1-deoxy-D-xylulose 5-phosphate reductoisomerase, putative | 0.1738 | 1 | 0.5 |
Treponema pallidum | 1-deoxy-D-xylulose 5-phosphate reductoisomerase | 0.1738 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 1-deoxy-D-xylulose 5-phosphate reductoisomerase | 0.1738 | 1 | 0.5 |
Mycobacterium ulcerans | 1-deoxy-D-xylulose 5-phosphate reductoisomerase | 0.1738 | 1 | 0.5 |
Plasmodium falciparum | 1-deoxy-D-xylulose 5-phosphate reductoisomerase | 0.1738 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable 1-deoxy-D-xylulose 5-phosphate reductoisomerase Dxr (DXP reductoisomerase) (1-deoxyxylulose-5-phosphate reductoisomeras | 0.0742 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | > 3 mg kg-1 | In vivo antagonism activity against dopamine D2 receptor was measured as emesis in dog when administered subcutaneously | ChEMBL. | 3397992 |
ED50 (functional) | > 3 mg kg-1 | In vivo antagonism activity against dopamine D2 receptor was measured as emesis in dog when administered subcutaneously | ChEMBL. | 3397992 |
ED50 (functional) | > 40 mg kg-1 | In vivo antagonistic activity against dopamine D2 receptor was measured as catalepsy in rat when administered subcutaneously | ChEMBL. | 3397992 |
ED50 (functional) | > 40 mg kg-1 | In vivo antagonism activity against D2 receptor was measured as stereotypy in rat when administered subcutaneously | ChEMBL. | 3397992 |
ED50 (functional) | > 40 mg kg-1 | In vivo antagonistic activity against dopamine D2 receptor was measured as catalepsy in rat when administered subcutaneously | ChEMBL. | 3397992 |
ED50 (functional) | > 40 mg kg-1 | In vivo antagonism activity against D2 receptor was measured as stereotypy in rat when administered subcutaneously | ChEMBL. | 3397992 |
Emetic episodes (functional) | = 2.3 | In vivo antagonism of cisplatin-induced emesis in ferret measured as emetic episodes, twice the dose of 3 mg/kg and in 3 ferrets | ChEMBL. | 3397992 |
Emetic episodes (functional) | = 3 | In vivo antagonism of cisplatin-induced emesis in dog measured as emetic episodes, twice the dose of 1 mg/kg in 2 dogs | ChEMBL. | 3397992 |
IC50 (binding) | > 1000 nM | In vitro antagonistic activity against Dopamine receptor D2 was evaluated for the inhibition of [3H]-spiperone binding | ChEMBL. | 3397992 |
IC50 (binding) | > 1000 nM | In vitro antagonistic activity against Dopamine receptor D2 was evaluated for the inhibition of [3H]-spiperone binding | ChEMBL. | 3397992 |
Protection (functional) | = 68 % | In vivo antagonism of cisplatin-induced emesis in ferret measured as percentage protection for twice the dose of 3 mg/kg and in 3 ferrets | ChEMBL. | 3397992 |
Protection (functional) | = 76 % | In vivo antagonism of cisplatin-induced emesis in dog measured as percentage protection for twice the dose of 1 mg/kg in 2 dogs | ChEMBL. | 3397992 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.